The phase III TULIP study met its primary endpoint of progression-free survival in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer—demonstrating a statistically significant improvement over physician’s choice.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
